Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Cypress Bioscience Inc. (Nasdaq: CYPB) has agreed to acquire Proprius Pharmaceuticals Inc., a San Diego-based drug developer focused on rheumatology and autoimmune diseases. The deal includes a $37.5 ...

Acquired line of diagnostic and prognostic tools will help the firm advance its therapy for fibromyalgia that is under FDA review. Cypress Bioscience will acquire Proprius Pharmaceuticals with an ...

Cypress Bioscience is to acquire Proprius Pharmaceuticals in a $75 million deal that will boost its product offering and justify its building of a sales force ahead of a potential launch for its ...

Cypress Bioscience, Inc. and Proprius Pharmaceuticals, Inc. has announced that Cypress will acquire Proprius in a transaction that includes an upfront payment of $37.5 million in cash as well as an ...

Proprius Pharmaceuticals Inc. agreed to pay up to $117 million to license a topical pain drug, Indaflex 2.5% indomethacin cream, from AlphaRx Inc. The Phase II product, a non-steroidal ...

Proprius Pharmaceuticals Inc., a San Diego-based drug developer focused on rheumatology and autoimmune diseases, has raised $11 million in Series A funding (with an option to expand up to $17 million) ...